IR@PKUHSC  > 北京大学临床肿瘤学院
学科主题临床医学
Sorafenib in combination with transarterial chemoembolization in Chinese patients with hepatocellular carcinoma: a subgroup interim analysis of the START trial
Han, Guohong1; Yang, Jijin2; Shao, Guoliang3; Teng, Gaojun4; Wang, Maoqiang5; Yang, Jianyong6; Liu, Zhaoyu7; Feng, Gansheng8; Yang, Renjie9; Lu, Ligong10; Chao, Yee11; Wang, Jianhua12
关键词hepatocellular carcinoma sorafenib transarterial chemoembolization
刊名FUTURE ONCOLOGY
2013-03-01
DOI10.2217/FON.13.11
9期:3页:403-410
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Oncology
资助者Bayer Healthcare Pharmaceuticals (Leverkusen, Germany) ; Bayer Healthcare Pharmaceuticals ; Bayer Healthcare Pharmaceuticals (Leverkusen, Germany) ; Bayer Healthcare Pharmaceuticals
研究领域[WOS]Oncology
关键词[WOS]TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION ; RANDOMIZED CONTROLLED TRIAL ; ENDOTHELIAL GROWTH-FACTOR ; LIPIODOL CHEMOEMBOLIZATION ; ANGIOGENESIS ; MANAGEMENT ; EXPRESSION ; THERAPY ; KINASES ; COHORT
英文摘要

Aim: The third interim results of the START trial showed encouraging safety and efficacy profiles, with a median time to progression of 9 months. This subgroup analysis presents results in Chinese patients enrolled in the START trial. Materials & methods: Sixty two Chinese patients (median age 52 years) with unresectable hepatocellular carcinoma had transarterial chemoembolization (TACE) performed with an emulsion of Lipiodol (R) (Guerbet, Paris, France) and doxorubicin (30-60 mg) followed by embolization with absorbable particles. Sorafenib (400 mg twice-daily) was administered continuously with dose holidays 4 days prior to and post TACE procedures. TACE was performed every 6-8 weeks and responses were assessed after 4-6 weeks and then every 3 months if no further TACE was indicated. Patients continued receiving sorafenib until disease progression or unacceptable toxicity occurred. Results: Thirty seven patients (59.68%) received no more than two TACE procedures. During sorafenib treatment (median duration 6.4 months; mean daily dose 787.6 mg), 75.8% of patients experienced adverse events, most commonly pyrexia (37.1%), diarrhea (27.4%), skin reactions (22.6%), alopecia (19.4%) and abnormal hepatic function (16.1%). The most common grade 3-4 adverse events were abnormal hepatic function (6.5%) and diarrhea (3.2%). The median time to progression and overall survival were 10.6 and 16.5 months, respectively, and the objective response and stable disease rates were 44.3 and 42.6%, respectively. Conclusion: The combination of the TACE and sorafenib proved both safe and effective in the treatment of Chinese patients with unresectable hepatocellular carcinoma.

语种英语
资助者Bayer Healthcare Pharmaceuticals (Leverkusen, Germany) ; Bayer Healthcare Pharmaceuticals ; Bayer Healthcare Pharmaceuticals (Leverkusen, Germany) ; Bayer Healthcare Pharmaceuticals
WOS记录号WOS:000315966900014
引用统计
被引频次:13[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/67039
专题北京大学临床肿瘤学院
作者单位1.Zhejiang Canc Hosp, Hangzhou, Zhejiang, Peoples R China
2.Fourth Mil Med Univ, Xijing Hosp, Xian 710032, Peoples R China
3.Second Mil Med Univ, Changhai Hosp, Shanghai, Peoples R China
4.Southeast Univ, Zhongda Hosp, Nanjing, Jiangsu, Peoples R China
5.Peoples Liberat Army Gen Hosp, Beijing, Peoples R China
6.Sun Yat Sen Univ, Affiliated Hosp 1, Guangzhou 510275, Guangdong, Peoples R China
7.China Med Univ, Shengjing Hosp, Shenyang, Peoples R China
8.Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Wuhan 430074, Peoples R China
9.Peking Univ, Beijing Canc Hosp, Beijing 100871, Peoples R China
10.Guangdong Gen Hosp, Guangzhou, Guangdong, Peoples R China
11.Vet Gen Hosp, Taipei, Taiwan
12.Fudan Univ, Zhongshan Hosp, Dept Radiol, Shanghai 200433, Peoples R China
推荐引用方式
GB/T 7714
Han, Guohong,Yang, Jijin,Shao, Guoliang,et al. Sorafenib in combination with transarterial chemoembolization in Chinese patients with hepatocellular carcinoma: a subgroup interim analysis of the START trial[J]. FUTURE ONCOLOGY,2013,9(3):403-410.
APA Han, Guohong.,Yang, Jijin.,Shao, Guoliang.,Teng, Gaojun.,Wang, Maoqiang.,...&Wang, Jianhua.(2013).Sorafenib in combination with transarterial chemoembolization in Chinese patients with hepatocellular carcinoma: a subgroup interim analysis of the START trial.FUTURE ONCOLOGY,9(3),403-410.
MLA Han, Guohong,et al."Sorafenib in combination with transarterial chemoembolization in Chinese patients with hepatocellular carcinoma: a subgroup interim analysis of the START trial".FUTURE ONCOLOGY 9.3(2013):403-410.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Han, Guohong]的文章
[Yang, Jijin]的文章
[Shao, Guoliang]的文章
百度学术
百度学术中相似的文章
[Han, Guohong]的文章
[Yang, Jijin]的文章
[Shao, Guoliang]的文章
必应学术
必应学术中相似的文章
[Han, Guohong]的文章
[Yang, Jijin]的文章
[Shao, Guoliang]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。